Golgi protein and other biochemical tumor markers in early detection of breast cancer in Iraqi subjects

Breast cancer is a complicated, worldwide health issue. Clinical practice relies on tumor markers, biochemicals linked to cancers. Golgi protein 73 (GP73), a trans-membrane protein in the Golgi apparatus, is a promising diagnostic for breast and other malignancies. We investigated breast cancer tumor markers, including human Golgi protein 73. Blood samples were taken from 116 breast cancer patients (42 newly diagnosed and 74 under treatment), 26 benign tumor cases, and 34 seemingly healthy controls. An enzyme-linked immune-sorbent assay measured HER2, PR, ER, and Ca15-3 tumor markers and human Golgi protein 73 blood levels. The mean ages of breast cancer patients were benign tumor (39.54 ± 13.969), recently diagnosed (48.14 ± 7.754), and under treatment (48 ± 9.798), whereas healthy controls were 46.82 ± 12.413 years. Patients and healthy controls had similar serum human Golgi protein 73 assay levels. Tumor marker testing were promising and beneficial for monitoring breast cancer patients. Our work emphasizes tumor markers, notably human Golgi protein 73, in breast cancer diagnosis and prognosis. While blood GP73 levels did not change between patients and healthy controls, tumor marker testing indicated promise for monitoring breast cancer patients throughout therapy and follow-up.